GSK’sGSK1.44%increase; green up pointing triangle cancer drug Jemperli cleared an important hurdle ahead of potentially expanding its European Union marketing permission, in a boost to the ...

GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant ...

GSK's cancer drug Jemperli cleared an important hurdle ahead of potentially receiving marketing permission from the European Medicines Agency. The British pharmaceutical giant said Monday that the ...

GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for Jemperli for the treatment of patients with locally advanced mismatch ...

GSK plc (GSK, GSK.L) announced the European Commission has approved Jemperli in combination with chemotherapy for first-line ...

The European Commission (EC) has approved GSK's Jemperli (dostarlimab) combined with chemotherapy that includes carboplatin and paclitaxel for the first-line treatment of primary advanced or ...

GSK plc GSK announced that the European Commission has granted approval for the expanded use of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary, advanced or ...

UU. (FDA) para Jemperli (dostarlimab) en el tratamiento de pacientes con cáncer rectal localmente avanzado con deficiencia de reparación de errores de emparejamiento (dMMR)/alta inestabilidad de ...

(RTTNews) - GSK plc (GSK, GSK.L) announced the European Commission has approved Jemperli in combination with chemotherapy for first-line treatment of adult patients with primary advanced or ...